Introduction

B
ronchial artery aneurysm (BAA) is seen in less than 1% of cases of selective bronchial arteriography. It is a potentially life-threatening condition, often requiring immediate therapy following diagnosis. Most patients are asymptomatic, however, massive hemoptysis and mediastinal hematomas are potentially devastating complications following their rupture. Although no direct etiology has been established, most cases of BAA are associated chronic inflammatory, infectious and vascular lung diseases. Bronchial artery to pulmonary artery (BA-PA) fistula is an exceedingly uncommon vascular anomaly which can be congenital or acquired. [1, 2] We herein report of a case of patient who presented with progressive dyspnea, found to have a BAA with associated BA-PA fistula. The patient was successfully treated with embolization using cyanoacrylate. She of daily living. She had no chest pain, back pain, recent illnesses, cough, or B symptoms. She had no history of smoking. Additional history was unremarkable. Physical examination was only notable for oxygen saturation of 95% at rest with mild, 7%-8%, desaturation after minimal exertion. Initial pulmonary function testing and echocardiogram with agitated saline were unremarkable.
A computed tomography (CT) pulmonary angiogram was significant for a single 1.2 cm right infrahilar nonspecific density that was suspicious for an arterial source [ Figure 1a ]. Therefore, a CT arteriogram was performed that revealed an intrapulmonary BAA [ Figure 1b ]. Bronchial artery angiography was then performed, further demonstrating the presence of a BAA with BA-PA fistula [ Figure 2a and b].
The patient underwent successful embolization of with cyanoacrylate [ Figure 3 ]. On 3-month follow-up evaluation, the patient noted that symptoms had ceased progressing and that she was no longer experiencing significant shortness of breath. During her 1-year postembolization follow-up, the patient remained stable with improvement of her dyspnea, and CT angiogram confirming durable bronchial artery occlusion without notable expansion of the BAA [ Figure 4 ].
Discussion
BAA is a rare phenomenon, and concomitant BA-PA fistula is even more uncommon. In one review of 13 cases of BAA, sizes of BAA ranged from 5 to 30 mm, [3] however, the size was not felt to be predictive of risk of rupture. Many BAAs remain asymptomatic until rupture. Because of the inherent instability and risk of rupture, current recommendations are that BAAs should be treated on identification. [4] Embolization is the treatment of choice, however, it is not without inherent risks.
Although suggestive of possible BAA, the initial CT pulmonary angiogram was suboptimal for BAA characterization. In addition, there was no evidence to suggest a pulmonary vascular fistula. However, on the CT arteriogram, the BAA was more clearly identified, but the fistula was not. Additionally, certain images may have misleadingly suggested bronchial artery to pulmonary vein (BA-PV) fistula [ Figure 1b] . In systemic-to-pulmonary vascular malformations, anomalous flow causes abnormal filling patterns on angiography which may result in misdiagnoses. [1] Thus, selective bronchial artery angiogram is preferable when such pathology is suspected. In this case, identification of a BA-PA fistula via selective angiography was important considering that the risks of embolization of isolated BAA versus BA-PA and/or BA-PV fistula may theoretically be different.
It is unclear if the risk of rupture of BAA with BA to pulmonary circulation fistula differs from BAA alone, as their description remains limited to case reports. When identified, such systemic-to-pulmonary arteriovenous malformations (AVM) can be congenital or acquired. [5] If acquired, they are most often associated with underlying pulmonary diseases such as bronchiectasis, tuberculosis, or other inflammatory disease. [1] Some have suggested that hypoxia itself can be a catalyst in angiogenesis of anomalous collaterals. [6] If BAA formation is indeed secondary to high-pressure gradients, and if rupture is the result of necessary release of tension, it would seem plausible that fistula formation could also have relieved tension and reduced risk of rupture. In this case, it remained unclear if BAA with fistula was the cause of her shortness of breath or a symptom of her underlying disease.
Had this been a BA-PV fistula, embolization would have presented the theoretical risk of inadvertent propagation of emboli to the systemic circulation. Inadvertent migration of embolized material is reported in up to 3% of bronchial artery embolization (BAE) cases, and air emboli in approximately 2% of cases. [7, 8] Bronchial artery embolization by itself presents the risk of inadvertent spinal artery embolization, with some original studies reporting a incidence of up to 6.5 percent. Ultimately, when weighed against the risks and consequences of rupture, and compounded by that lack of alternative explanations for the patient's shortness of breath, the decision was made to proceed with embolization.
Finally, there are an increasing number of options and techniques for embolization. [9] The choice of the embolic agent should be dependent on durability of occlusion, size of occluded vessel, and ease of delivery. [10] It has been suggested that coils be avoided as they frequently require proximal placement which may preclude future embolization. [11] In cases of BAE for management of hemoptysis, recurrence rates range from 10% to 55% after as long as 46 months. [10] Therefore, follow-up imaging may often be indicated to verify durable occlusion.
Conclusions
While embolization of BAA is widely accepted as the treatment of choice, BAA complicated by fistulation to the pulmonary circulation resulting in a systemic-to-pulmonary AVM represents an uncommon challenge to management. CT angiogram alone may be insufficient for identification of a fistulous tract therefore, selective bronchial artery angiogram is recommended. Finally, a multidisciplinary discussion is instrumental in selecting the optimal therpeutic modality, followed by a thorough review of its risks, alternatives, and benefits with the patient.
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